(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
France, Germany, Italy summon Iranian envoys over 'unbearable, inhumane' regime crackdown - 2The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
- 3Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
- 4Picking Childcare Administrations for Your Loved ones
- 5Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
- Do you lean your seat back on the plane? These travel pros — and real-life couple — won't do it.
- Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
- A definitive Manual for Internet Mastering and Expertise Improvement
- Exhaustive Experiences into Prudent Senior Living in the UK
- Anger as German family business group opens talks with far-right AfD
- Where America’s CO2 emissions come from – what you need to know, in charts
- Israel faces widespread condemnation as NGO ban comes into effect
- ‘Downton Abbey: The Grand Finale’ hits streaming: How to watch, cast info and everything you need to know
- A Sweet Choice: Pick Your #1 Cake!
